Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I SAD/MAD/food-effect study of PTC857 in healthy volunteers
NL-OMON49571Phase 1Active, not recruiting
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) comparing PTC857 with Placebo (2 arms). Primary endpoints: Overall safety profile after single ascending dose, Overall safety profile after multiple ascending doses and 1 more. Started Jun 2020; status: active, not recruiting.
02
Drugs
utreloxastat
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON49571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49571.